LTR Pharma Limited

A$0.42As of Sun 8 Nov 2026, 12:00 UTC
ASX:LTPHealthcare
Country Australia
PE (Fwd) •••
TSR 3Y CAGR 7.13%
Div yield —
ROE (54.73%)
Biotechnology
Beta (5Y) 2.24
PE TTM —
TSR TTM (16.00%)
Mkt cap A$76.56M
ROIC (33.79%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.425
1.10%
(68.19%)
Hold 11|0|4|9|7
2Q26
3Q26
4Q26
1Q27
Earnings per share$
0.01
0.01
0.01
0.01
5.07%
15.05%
23.56%
21.76%
Revenue$M
4.088
4.320
4.259
4.289
10.48%
17.75%
13.11%
10.57%
Peers (US$52.58M)
Cap (US$)
PE
52.40M
—
Capital
TTM
5Y
10Y
Leveragex
7.094
2.233
1.965
EBIT/Intx
6.885
0.121
0.101
Own earn%
(58.00)
(99.76)
(102.54)
Sh yield%
50.23
28.05
31.25
Owners
Insiders/Inst%
6.64
26.42
Short interest%
5.81
SBC / revenue%
3.98
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
20–27
$1 testx
—
Incr. ROIC%
1